证券代码：000705 证券简称：浙江震元 公告编号：2025-030 浙江震元股份有限公司 关于增补第十一届董事会董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江震元股份有限公司（以下简称"公司"）于 2025 年 8 月 4 日 召开第十一届董事会 2025 年第三次临时会议，审议通过了《关于增 补第十一届董事会董事的议案》。 依照《公司法》《公司章程》等相关规定，经董事会提名委员会 审核，公司董事会同意提名周巧米女士为公司第十一届董事会董事候 选人（简历附后），任期自股东大会审议通过之日起至第十一届董事 会任期届满之日止。该事项需提交股东大会审议通过后生效。 本次增补董事完成后，公司董事会中兼任高级管理人员的董事人 数，总计未超过公司董事总数的二分之一。 特此公告。 周巧米，女，1979 年 3 月出生，浙江诸暨人，中共党员，研究 生学历，管理硕士。曾任共青团诸暨市委书记、党组书记，浙江省绍 兴市慈善工作办公室主任，浙江省绍兴市民政局副局长、党委委员， 浙江省新昌县副县长、县政府党组成员，浙江省新昌县委常委、纪委 书记、监察委员会主任，浙 ...

证券代码：000705 证券简称：浙江震元 公告编号：2025-031 浙江震元股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 1.股东大会届次：2025 年第一次临时股东大会 2.股东大会的召集人：公司董事会。2025 年 8 月 4 日，公司第十 一届董事会 2025 年第三次临时会议审议通过了《关于召开 2025 年第 一次临时股东大会的议案》。 3. 会议召开的合法、合规性：本次股东大会会议召开符合《公司 法》、《公司章程》的相关规定。 4.会议召开日期、时间：2025 年 8 月 20 日下午三时召开现场会议 网络投票时间：2025 年 8 月 20 日 其中：通过深圳证券交易所交易系统进行网络投票的时间为一天， 具体时间为：2025 年 8 月 20 日 9:15-9:25、9:30-11:30、13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 20 日 9:15-15:00。 5.会议的召开方式：本次股东大会采用现场 ...

浙江震元第十一届董事会 2025 年第三次临时会议决议公告 证券代码：000705 证券简称：浙江震元 公告编号：2025-028 浙江震元股份有限公司第十一届董事会 2025年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江震元股份有限公司第十一届董事会 2025 年第三次临时会议通 知于 2025 年 8 月 1 日以书面、通讯等形式发出，2025 年 8 月 4 日以通 讯形式召开。会议应出席董事 11 人，本次会议应通讯表决方式出席会 议的董事 11 人，实际通讯表决方式出席会议董事 11 人。本次董事会 会议的召开符合有关法律、行政法规、部门规章、规范性文件和公司 章程的规定。 二、董事会会议审议情况 表决结果：11 票同意，0 票反对，0 票弃权。 2、审议通过《关于增补第十一届董事会董事的议案》； 具体详见同日披露于巨潮资讯网（http://www.cninfo.com.cn） 的《关于增补第十一届董事会董事的公告》（公告编号：2025-030）， 表决结果：11 票同意，0 票反对，0 票弃权 ...

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Market Overview - The A-share market opened slightly lower on July 17 but then experienced a rebound, with all three major indices showing positive performance, particularly the ChiNext index which rose nearly 1% [2] - The total market capitalization reached 14.20 trillion CNY, with a trading volume of 7698.06 million hands and a turnover rate of 1.46% [3] Pharmaceutical Sector - The pharmaceutical sector saw a significant surge, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical and Chengdu Xian Dao, both reaching a 20% increase [4][5] - Notable stocks in the pharmaceutical sector included: - Chengdu Xian Dao: 21.46 CNY, up 20.02% - Weikang Pharmaceutical: 20.71 CNY, up 19.99% - Other stocks like Lifespring Pharmaceutical and Zhejiang Zhenyuan also saw increases of around 10% [5][6] - The Hong Kong pharmaceutical and biotechnology sector also experienced notable gains, with companies like Fudan Zhangjiang and Kanyin Biotech showing significant price increases [6] Robotics Sector - The humanoid robot concept stocks remained active, with Nanjing Julong hitting the daily limit up of 20%, and other companies like Dongshan Precision and Taijing Technology also seeing substantial gains [7][8] - On July 17, the stock of Aowei New Materials achieved a 20% limit up, marking its seventh consecutive trading day of gains, with a closing price of 27.89 CNY [10][11] Policy Impact - The National Healthcare Security Administration recently announced the initiation of the 11th batch of centralized drug procurement, which will include 55 drug varieties, focusing on mature "old drugs" while excluding innovative drugs from the procurement list [6]

Group 1 - The concept of Helicobacter pylori has seen an increase of 1.93%, ranking 9th among concept sectors, with 62 stocks rising, including Rundu Co., Aosaikang, and Zhejiang Zhenyuan hitting the daily limit [1][2] - Leading gainers in the Helicobacter pylori sector include Laimei Pharmaceutical, Hanyu Pharmaceutical, and Te Yi Pharmaceutical, with increases of 8.48%, 6.41%, and 5.49% respectively [1] - The sector experienced a net inflow of 774 million yuan from main funds, with 49 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow, led by Hanyu Pharmaceutical with 166 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio are Rundu Co. at 42.20%, Zhejiang Zhenyuan at 29.25%, and ST Huluwa at 16.55% [3][4] - Hanyu Pharmaceutical had a trading volume of 165.89 million yuan with a net inflow ratio of 6.26%, while Rundu Co. had a trading volume of 144.66 million yuan [3][4] - The overall market performance shows a mixed trend, with some stocks like Zhijiang Biology, ST Suwu, and Dongfang Ocean experiencing declines of 6.08%, 5.02%, and 4.23% respectively [6][7]

Group 1: Robotics Sector - Several companies in the robotics sector have seen significant stock price increases, with Zhejiang Rongtai rising by 10.00%, Jujie Microfiber by 20.02%, and Houtai Co. by 10.01% [2][3] - Other notable mentions include Fuda Co. at 10.01%, Donggang Co. at 9.96%, and Junhe Co. at 9.99%, all attributed to the robotics theme [2] Group 2: Innovative Pharmaceuticals - The innovative pharmaceutical sector is experiencing a surge, with Lianhuan Pharmaceutical achieving 9.98% increase over eight consecutive trading days, and Wanbangde and Aosaikang both rising by 10.01% and 10.02% respectively [5][7] - Zhejiang Zhenyuan and Rundu Co. also reported first board appearances with increases of 9.98% and 10.03% respectively, driven by the innovative drug theme [5] Group 3: Performance Surprises - Over 57% of listed companies have reported positive performance forecasts for the first half of the year, with a nearly 70% increase in total net profit compared to the same period last year [8] - Companies like Dayilong and Huahong Technology have seen stock increases of 10.03% and 10.04% respectively, attributed to strong performance and market conditions [9] Group 4: Electric Vehicles - The automotive sector is thriving, with production and sales exceeding 15 million units in the first half of the year, marking a double-digit growth year-on-year [12] - Companies such as Zhejiang Liming and Tianlong Co. have reported stock increases of 9.98% and 10.00% respectively, linked to the automotive and chip sectors [13] Group 5: AI Applications - The AI application sector is gaining traction, with companies like Puyuan Information and Keri International seeing stock increases of 20.01% and 14.36% respectively, driven by advancements in AI infrastructure [24][23] Group 6: Digital Currency - The digital currency sector is witnessing increased attention, with over five cities mentioning stablecoins in recent discussions, leading to stock increases for companies like Jinshi Technology and Dongxin Peace [28][29]

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Core Points - Zhejiang Zhenyuan Co., Ltd. received an inquiry letter from Shenzhen Stock Exchange regarding its application for issuing shares to specific targets [1][2] - The company, along with relevant intermediaries, has conducted thorough research and updates on the issues raised in the inquiry letter and the fundraising prospectus [1][2] - The issuance of shares to specific targets is subject to approval from Shenzhen Stock Exchange and the China Securities Regulatory Commission [2] Summary by Sections - **Company's Actions** - The company received the inquiry letter on November 14, 2024, and has updated its fundraising prospectus accordingly [1] - The updated documents were disclosed on December 6, 2024, on the official information platform [1] - **Regulatory Approval** - The issuance of shares requires approval from both Shenzhen Stock Exchange and the China Securities Regulatory Commission [2] - There is uncertainty regarding the approval process and timeline for the issuance [2] - **Investor Communication** - The company will fulfill its information disclosure obligations based on the progress of the issuance [2] - Investors are advised to make cautious decisions and be aware of investment risks [2]

浙江震元股份有限公司 2024 年向特定对象发行股票募集说明书（申报稿） 证券简称：浙江震元 证券代码：000705 浙江震元股份有限公司 （注册地址：浙江省绍兴市稽山街道延安东路 558 号） 2024 年向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） （杭州市五星路 201 号） 二〇二五年六月 浙江震元股份有限公司 2024 年向特定对象发行股票募集说明书（申报稿） 声 明 本公司及全体董事、监事、高级管理人员承诺本募集说明书内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承 担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证 募集说明书中财务会计报告真实、完整。 中国证券监督管理委员会、深圳证券交易所对本次发行所作的任何决定或意 见，均不表明其对公司所发行证券的价值或者投资人的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益 ...